Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRS Carpenter Technology

Pre-Mkt 12-17 05:15:47 EST

321.49

-2.13

-0.66%

High326.27	Low317.37	Vol991.52K
Open321.18	D1 Closing323.62	Amplitude2.75%
Mkt Cap16.02B	Tradable Cap15.59B	Total Shares49.82M
T/O318.22M	T/O Rate2.04%	Tradable Shares48.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRS","market":"US","secType":"STK","nameCN":"Carpenter Technology","latestPrice":321.49,"timestamp":1765918800000,"preClose":323.62,"halted":0,"volume":991515,"delay":0,"floatShares":48497746,"shares":49818822,"eps":8.177718,"marketStatus":"Pre-Mkt","change":-2.13,"latestTime":"12-17 05:15:47 EST","open":321.18,"high":326.27,"low":317.3692,"amount":318220096.0995,"amplitude":0.027504,"askPrice":324.38,"askSize":4,"bidPrice":321.49,"bidSize":3,"shortable":3,"etf":0,"ttmEps":8.177718,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765981800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":321.49,"dividendRate":0.002488,"postHourTrading":{"tag":"盘后","latestPrice":321.49,"preClose":321.49,"latestTime":"19:51 EST","volume":136641,"amount":43928682.97,"timestamp":1765932667526},"volumeRatio":0.7218380405278423,"impliedVol":0.4268,"impliedVolPercentile":0.1566},"requestUrl":"/m/hq/s/CRS/tweets","defaultTab":"tweets","newsList":[{"id":"2592951573","title":"Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592951573","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592951573?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:00","pubTimestamp":1765933200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application  for XPOVIO  for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma  after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.Antengene has also developed AnTenGager, a proprietary T cell engager 2.0 platform featuring \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS","market":"us","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","CRS","LU2065731478.USD","IND","IE00B19Z4B17.USD","IE0031619046.USD","IE00B66KJ199.SGD","IND.AU","IE00B7SZL793.SGD","LU0963586101.USD","BK7095","CRS.AU","BK4006"],"gpt_icon":0},{"id":"2591902647","title":"Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2591902647","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591902647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:48","pubTimestamp":1765810080,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  stock rose Monday, with a session volume of 6.80 million compared to the average volume of 696.68 thousand as per data from Benzinga Pro.The clinical-stage biopharmaceutical company shared topline data from the KYSA-8 Phase 2 trial of mivocabtagene autoleucel  in stiff person syndrome .Miv-cel is a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation.Also Read: Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026. Stiff Person Syndrome is a rare autoimmune neurological disorder causing progressive muscle stiffness, rigidity, and painful spasms, primarily in the torso and limbs, triggered by stimuli like noise or touch, leading to falls and disability as it worsens over time.It results from the immune system mistakenly attacking nerve cells controlling muscle movement.The single-arm registrational Phase 2 trial dosed 26 patients who had an inadequate response with non-approved treatment options, and received a single d","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4006","LU2065731478.USD","BK4187","BK4139","KYTX","BK4588","CRS","LU0963586101.USD","DSI","BK4585","IE00B66KJ199.SGD","IE0031619046.USD","IE00B7SZL793.SGD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2591439736","title":"Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2591439736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591439736?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":"Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205250/0/en/Kyverna-Therapeutics-Announces-Positive-Topline-Data-from-Registrational-KYSA-8-Trial-of-Miv-cel-KYV-101-in-Stiff-Person-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139","BK4022","DSI","IE00B7SZL793.SGD","CRS","IE00B66KJ199.SGD","BK4585","BK4588","BK4230","BK4006","BK4187","IE0031619046.USD","CAR","LU0963586101.USD","IE00B19Z4B17.USD","LU2065731478.USD"],"gpt_icon":0},{"id":"2590564305","title":"NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590564305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590564305?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:30","pubTimestamp":1765402200,"startTime":"0","endTime":"0","summary":"Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203528/0/en/NovaBridge-Presents-Positive-Ragistomig-Phase-1-Dose-Expansion-Data-at-ESMO-IO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","BK4006","LFT","BK4107","IE00B66KJ199.SGD","LU0210528500.USD","LU2487616109.SGD","BK4588","IE00B19Z4B17.USD","LU0963586101.USD","LU0053666078.USD","BK4585","BK4187","CRS","IE0031619046.USD","BK4110","LU2065731478.USD","L"],"gpt_icon":0},{"id":"1152131178","title":"IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152131178","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152131178?lang=en_us&edition=fundamental","pubTime":"2025-12-09 13:18","pubTimestamp":1765257530,"startTime":"0","endTime":"0","summary":"Recently, another innovative biopharmaceutical company officially submitted its IPO application to the Hong Kong Stock Exchange. According to disclosures, Zhejiang Shima Pharmaceutical Co., Ltd.-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","BK4107","CRS","BK4588","ADC","IE00B19Z4B17.USD","BK4187","LU0053666078.USD","BK4231","L","LU2487616109.SGD","LU0210528500.USD","ORR","LU0963586101.USD","IE0031619046.USD","LU2065731478.USD","BK4585","BK4080","IE00B7SZL793.SGD","BK4006"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE0031619046.USD","LU0963586101.USD","LU2065731478.USD","PFS","BK4109","BK4161","CR","BK4187","ASH","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4006","CRS","OS","ORR","LU2463526074.USD","BK4097","BK4211"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4132","BK4187","BK4007","LENZ","AFG","BK4533","IE00B7SZL793.SGD","LU2355687059.USD","BK4585","UCL","LU1571399168.USD","BK4117","BK4588","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU0963586101.USD","CR","LU0985320562.USD","CRS","ASH","BK4107","FC","LU1699723380.USD","LU2463526074.USD","OS","BK4161","BK4109","BK4139","BK4539","BK4230","BK4006","CAR","LU2065731478.USD","BK4097","ORR","BK4123","IE0031619046.USD","ALL"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","ASH","BK4226","BK4161","LU0545562505.USD","CRS","BK4548","BK4106","BK4109","BK4187","BR","IPI","BK4097","LU2463526074.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4006","BK4093","IE0031619046.USD","BK4588","LU0390134368.USD","LU1228905540.USD","BK4211","BK4195","LU0963586101.USD","ORR","OS","IE0034235188.USD","PFS","IE0009354923.USD","CR","IE00B19Z4B17.USD","BK4585"],"gpt_icon":0},{"id":"2588011633","title":"XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011633","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011633?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:00","pubTimestamp":1764752400,"startTime":"0","endTime":"0","summary":"- XPOVIO  has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma  when used together with dexamethasone , and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma  and as a combination therapy when used together with bortezomib and dexamethasone  for MM patients who received at least one prior therapy.- XPOVIO is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO is set to benefit more patients in Hong Kong.- XPOVIO has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets .Antengene Corporation Limited  is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical t","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/xpovio-approved-in-hong-kong-for-two-additional-indications-in-multiple-myeloma-and-diffuse-large-b-cell-lymphoma-302631561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","LU2065731478.USD","BK4187","IE00B66KJ199.SGD","IND","CRS.AU","CRS","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4006","LU0963586101.USD","IE0031619046.USD","BK7095"],"gpt_icon":0},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK4218","PK","IE00B66KJ199.SGD","CRS","BK4181","ORR","BK4006","IE0031619046.USD","IND","IE00B19Z4B17.USD","ORR.AU","BK4187","IE00B7SZL793.SGD","CRS.AU","ADC.AU","LU2065731478.USD","LU0963586101.USD","BK4080","BK4231","BK7095","ADC"],"gpt_icon":0},{"id":"2588975772","title":"Elizabeth A. Socci, VP and Chief Accounting Officer, Reports Disposal of Carpenter Technology Corporation Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588975772","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588975772?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:45","pubTimestamp":1764611130,"startTime":"0","endTime":"0","summary":"Elizabeth A. Socci, Vice President, Controller & Chief Accounting Officer, reported a disposal of common shares of Carpenter Technology Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carpenter Technology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3gWMxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Elizabeth A. Socci, VP and Chief Accounting Officer, Reports Disposal of Carpenter Technology Corporation Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","LU0963586101.USD","BK4187","BK4006","IE00B19Z4B17.USD","CRS","LU2065731478.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2586782177","title":"Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782177","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782177?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:52","pubTimestamp":1764334320,"startTime":"0","endTime":"0","summary":"BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd.  announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel  , has received new drug marketing approvalfrom the China National Medical Products Administration . This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma  after two or more lines of systemic therapy. This is the second approved indicationin China for Ina-cel, following its initial approval in November 2023 for the treatment of adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia . This milestone marks the first proprietary CD19 CAR-T product in China with full intellectual property rights to become the only CAR-T cell therapy product in the country that covers both leukemia and lymphoma, the two major hematological oncology indications.Professor Dehui Zou, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences :","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/inaticabtagene-autoleucel-yorwidatm-new-drug-application-for-lymphoma-approved-chinas-innovative-car-t-enters-a-new-era-of-dual-indications-302628059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK7095","LU2065731478.USD","BK4187","CRS.AU","IE00B19Z4B17.USD","BK4022","BK4230","ORR","CRS","ORR.AU","LU0963586101.USD","IE00B66KJ199.SGD","BK4161","CR","IE0031619046.USD","CAR","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2586261792","title":"$700 Million Refinancing Could Be A Game Changer For Carpenter Technology (CRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261792","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261792?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:18","pubTimestamp":1764173892,"startTime":"0","endTime":"0","summary":"Earlier this month, Carpenter Technology Corporation completed a US$700 million private offering of 5.625% senior notes due 2034 and amended its credit agreement to increase revolving commitments to US$500 million and extend the credit facility maturity to 2030.\nThis refinancing initiative is intended to repay higher-interest debt and is expected to enhance the company's financial flexibility through improved liquidity and reduced future interest expenses.\nWe'll explore how Carpenter...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/700-million-refinancing-could-be-a-game-changer-for-carpente","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/700-million-refinancing-could-be-a-game-changer-for-carpente","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4187","IE00B7SZL793.SGD","LU2065731478.USD","CRS.AU","BK4006","LU0963586101.USD","IE00B66KJ199.SGD","CRS","BK7095","IE00B19Z4B17.USD","IE0031619046.USD"],"gpt_icon":0},{"id":"2585532163","title":"Carpenter Technology Closes $700 Million Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2585532163","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585532163?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:18","pubTimestamp":1763677121,"startTime":"0","endTime":"0","summary":"Carpenter Technology (CRS) reported late Thursday the closing of its $700 million offering of 5.625% senior notes due 2034.The firm said it plans to use the proceeds to help redeem 6.375% senior notes due 2028 and 7.625% senior notes due 2030.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRS.AU","BK4006","CRS","LU2065731478.USD","LU0963586101.USD","BK7095","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4187"],"gpt_icon":0},{"id":"2585168098","title":"BRIEF-Carpenter Technology Corp On Nov 20, Co And Others Entered Into Amendment And Restatement Of Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168098","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168098?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:08","pubTimestamp":1763676496,"startTime":"0","endTime":"0","summary":"BRIEF-Carpenter Technology Corp On Nov 20, Co And Others Entered Into Amendment And Restatement Of Credit FacilityNov 20  - Carpenter Technology Corp CRS.N:CARPENTER TECHNOLOGY CORP: ON NOV 20, CO AND OTHERS ENTERED INTO AMENDMENT AND RESTATEMENT OF CREDIT FACILITYCARPENTER TECHNOLOGY CORP - AMENDMENT INCREASES REVOLVING COMMITMENTS TO $500 MILLION - SEC FILINGCARPENTER TECHNOLOGY CORP - CREDIT FACILITY MATURITY DATE EXTENDED TO FIFTH ANNIVERSARY OF CLOSING OF AMENDMENT - SEC FILINGFurther company coverage: CRS.N ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","CRS","LU0963586101.USD","LU2065731478.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4187","IE0031619046.USD","BK4006"],"gpt_icon":0},{"id":"2585168694","title":"Carpenter Technology Corp - Amendment Increases Revolving Commitments to $500 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168694?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:45","pubTimestamp":1763675115,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1H6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065731478.USD","IE00B19Z4B17.USD","LU0963586101.USD","BK4006","BK4187","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","CRS"],"gpt_icon":0},{"id":"2585168692","title":"Carpenter Technology Corp: on Nov 20, Co and Others Entered Into Amendment and Restatement of Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168692?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:45","pubTimestamp":1763675115,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRS","LU0963586101.USD","IE00B19Z4B17.USD","BK4187","IE0031619046.USD","IE00B7SZL793.SGD","BK4006","LU2065731478.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2585150350","title":"Press Release: Carpenter Technology Corporation Announces Closing of $700.0 Million Private Offering of 5.625% Senior Notes Due 2034 and Amendment of Credit Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150350","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150350?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:15","pubTimestamp":1763673300,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Nov. 20, 2025  -- Carpenter Technology Corporation   announced today the closing of its previously announced offering of $700.0 million aggregate principal amount of 5.625% senior notes due 2034  through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to certain persons outside of the United States pursuant to Regulation S, each under the Securities Act of 1933, as amended . The Company intends to use the net proceeds from the offering of the Notes, together with cash on hand, to redeem in full its 6.375% senior notes due 2028, including any accrued but unpaid interest due, and redeem in full its 7.625% senior notes due 2030, including any accrued but unpaid interest and premium due.This press release is neither an offer to sell nor a solicitation of an offer to buy the Notes and shall not constitute an offer, solicitation or sale, nor is it an offer to purchase or the solicitation of an offer to sell the No","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Carpenter Technology Corporation Announces Closing of $700.0 Million Private Offering of 5.625% Senior Notes Due 2034 and Amendment of Credit Agreement","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LU0963586101.USD","CRS","IE00B7SZL793.SGD","BK4187","IE0031619046.USD","LU2065731478.USD","IE00B66KJ199.SGD","BK4006"],"gpt_icon":0},{"id":"2584153997","title":"PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2584153997","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584153997?lang=en_us&edition=fundamental","pubTime":"2025-11-20 23:12","pubTimestamp":1763651520,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01  have been accepted for oral presentations at the 2025 American Society of Hematology  Annual Meeting.The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia  and r/r B-cell Non-Hodgkin Lymphoma , including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies  support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.Safety: PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade 1 Cytokine Release Syndrome  and no Grade 1 Immune Effector Cell-Associated Neu","market":"us","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bios-pmb-ct01-baffr-car-t-data-selected-for-two-oral-presentations-at-67th-ash-2025-annual-meeting-302621280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IE0031619046.USD","LU0963586101.USD","ASH.AU","LU2065731478.USD","BK4109","BK4230","BK4022","BK4161","CR","BK4187","ASH","HCT.AU","IE00B19Z4B17.USD","IE00B7SZL793.SGD","CRS.AU","BK7057","BK7111","BK4006","BK7501","IE00B66KJ199.SGD","CRS","CAR","LU2463526074.USD"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4006","ORR.AU","PRGS","BK4187","BK7508","ORR","IE0031619046.USD","BK4161","LU2065732104.USD","ACR.AU","BK4097","CRS","BK7096","ACR","IND.AU","IE00B66KJ199.SGD","LU0963586101.USD","BK4110","IE00B7SZL793.SGD","CR","IE00B19Z4B17.USD","CRS.AU","LU2065731478.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carpentertechnology.com","stockEarnings":[{"period":"1week","weight":0.0699},{"period":"1month","weight":-0.0273},{"period":"3month","weight":0.3184},{"period":"6month","weight":0.281},{"period":"1year","weight":0.8323},{"period":"ytd","weight":0.8943}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.007065},{"month":2,"riseRate":0.644444,"avgChangeRate":0.022439},{"month":3,"riseRate":0.533333,"avgChangeRate":0.000821},{"month":4,"riseRate":0.565217,"avgChangeRate":0.044931},{"month":5,"riseRate":0.543478,"avgChangeRate":0.024379},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.000496},{"month":7,"riseRate":0.5,"avgChangeRate":0.022964},{"month":8,"riseRate":0.456522,"avgChangeRate":-0.007895},{"month":9,"riseRate":0.608696,"avgChangeRate":-0.003285},{"month":10,"riseRate":0.347826,"avgChangeRate":-0.015075},{"month":11,"riseRate":0.717391,"avgChangeRate":0.060126},{"month":12,"riseRate":0.630435,"avgChangeRate":0.016626}],"exchange":"NYSE","name":"Carpenter Technology","nameEN":"Carpenter Technology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Carpenter Technology,CRS,Carpenter Technology股票,Carpenter Technology股票老虎,Carpenter Technology股票老虎国际,Carpenter Technology行情,Carpenter Technology股票行情,Carpenter Technology股价,Carpenter Technology股市,Carpenter Technology股票价格,Carpenter Technology股票交易,Carpenter Technology股票购买,Carpenter Technology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction